<DOC>
	<DOCNO>NCT00381017</DOCNO>
	<brief_summary>This Phase 3b , randomize , open-label , parallel-group , multi-center , multi-national study low-dose maintenance Peg interferon alpha-2b ( Peg-Intron® ) subject human immunodeficiency virus-hepatitis C virus ( HIV-HCV ) co-infection . The primary objective compare end study efficacy Peg-Intron® monotherapy ( 0.5 µg/kg subcutaneously weekly 24-36 month ) versus standard supportive care , use time follow clinical event ( death , decompensation , liver transplant , hepatocellular carcinoma [ HCC ] ) endpoint .</brief_summary>
	<brief_title>Effects Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care Patients With Cirrhotic Hepatitis C With HIV ( Study P04371 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Age least 18 year &lt; 70 year , either sex race . Detectable plasma hepatitis C virus ( HCV ) RNA ( genotype HCV permit ) . Cirrhosis liver within last five year . Compensated liver disease ( ChildPugh &lt; 8 hepatic encephalopathy &lt; = 1 . No evidence hepatocellular carcinoma ( HCC ) serum alpha fetoprotein ( AFP ) &lt; 100 ng/mL within two month randomization/study enrollment . Varices result via endoscopy within last six month time screen . Serologic evidence human immunodeficiency virus1 . CD4 cell count &gt; =100 /µL . Platelet number least 50000 mm**3 . Neutrophil count least 750 mm**3 . Hemoglobin &gt; 9.0 mg % . Serum thyroid stimulate hormone level within normal limit , regardless treatment L thyroxin . Hemoglobin A1c ( HbA1c ) &lt; 8.5 % , demonstrate control diabetes , applicable . Written clearance ophthalmologist must present subject history hypertension diabetes prior treatment start . Creatinine clearance &gt; 50 mL/min , assess indirect calculation method . Demonstrate stable status HIV1 infection . On stable antiretroviral therapy ( HAART ) least 6 week prior baseline , expectation HAART regimen ( drug dosage ) remain unaltered first 8 week study OR Willing delay initiation HAART therapy least 6 week ( subject HAART least 8 week prior randomization ) . `` Structured treatment interruption '' permit study . Counseled appropriate use birth control study , confirm principal investigator subinvestigator . Free clinically significant disease ( HCV HIV ) would interfere study evaluation . Female pregnant , intend become pregnant study within two month study completion , nursing . Male subject whose partner want become pregnant . Using silymarin . Positive test screen antiHAV IgM Ab , HBsAg , antiHBc IgM Ab , HBeAg . Any cause liver disease chronic hepatitis C. Suspected hypersensitivity interferon . History liver decompensation status evidence bleed esophageal varix , sign current bleeding , significant ascites , hepatic encephalopathy , jaundice condition consistent decompensated liver disease . Present lesion suspicious hepatic malignancy screen image . Any active malignant disease , suspicion , history malignant disease within 5 year prior study enrollment ( except adequately treat basal cell carcinoma ) . Known coagulation hemoglobin disease . Organ transplant , except corneal hair transplant . Any known preexisting medical condition , investigator 's opinion , could interfere subject 's participation completion study , major depressive disorder . Active HIVrelated opportunistic infection and/or malignancy require systemic therapy . Evidence know severe retinopathy . Subject observe designate washout period prohibit medication . Participating hepatitis C clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>